Feb 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
Jun 19, 2019
Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Oct 25, 2018
Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
Aug 31, 2018
AgileOne Selected to Serve as Bristol-Myers Squibb's Contingent Workforce Talent Solutions Partner
Mar 07, 2018
IFM Therapeutics and Bristol-Myers Squibb Awarded 2017 Deal of the Year by Clarivate Analytics
Feb 14, 2018
Bristol-Myers Squibb Demonstrates Their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program
Nov 11, 2017
First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017
Sep 22, 2017
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
Jun 16, 2017
Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek Co., Ltd.
Jun 05, 2017
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Jun 03, 2017
Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
May 30, 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration